Loading
Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma.
Jason Westin was first author of the ZUMA-7 overall survival report, which showed axicabtagene ciloleucel improves survival compared with standard chemoimmunotherapy and transplant in primary refractory or early relapsed large B-cell lymphoma, the first randomised survival benefit for a CAR-T therapy and the trial that moved CAR-T into second line. He leads the Smart Start precision-medicine trials in DLBCL and lymphoma clinical research at MD Anderson.
The reason second-line CAR-T is offered with axicabtagene ciloleucel or lisocabtagene maraleucel rather than tisagenlecleucel. The trial is also the strongest evidence in the field that the interval between apheresis and infusion, and what is given during it, is part of the treatment rather than logistics around it.
ZUMA-7 rewrote second-line treatment for aggressive lymphoma: patients whose disease returns within a year of R-CHOP should be offered CAR-T rather than salvage chemotherapy and transplant. It is also one of the few cell-therapy trials to show an overall survival benefit despite crossover. Patients relapsing later than 12 months were not studied and transplant remains standard for them if chemosensitive.
Shares ZUMA-7, Axicabtagene ciloleucel, MD Anderson Cancer Center, CD19 and the tags lymphoma, car-t.
Shares ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, ZUMA-7, Axicabtagene ciloleucel, CD19.
Shares CD19, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, CAR-T cell therapy, Diffuse large B-cell lymphoma and the tags lymphoma, car-t.
Shares MD Anderson Cancer Center, CD19, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, CAR-T cell therapy and the tags lymphoma, car-t.
Shares Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, ZUMA-7, CD19.
Shares Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, ZUMA-7, Axicabtagene ciloleucel.
Shares ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, ZUMA-7, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma.